Cancer therapy in mice using a pure population of CD8
Adoptive cell therapy
Immunocytokines
Immunotherapy
Retroviral antigens
T cells
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
03
12
2020
accepted:
08
03
2021
pubmed:
3
4
2021
medline:
16
10
2021
entrez:
2
4
2021
Statut:
ppublish
Résumé
There is a growing interest in the use of patient-derived T cells for the treatment of various types of malignancies. The expansion of a polyclonal and polyspecific population of tumor-reactive T cells, with a subsequent infusion into the same donor patient, has been implemented, sometimes with positive results. It is not known, however, whether a set of T cells with a single antigen specificity may be sufficient for an effective therapy. To gain more insights in this matter, we used naturally occurring T cells recognizing a retroviral peptide (AH1), which is endogenous in many tumor cell lines of BALB/c origin and which serves as potent tumor rejection antigen. We were able to isolate and expand this rare population of T cells to numbers suitable for therapy experiments in mice (i.e., up to 30 × 10
Identifiants
pubmed: 33796916
doi: 10.1007/s00262-021-02912-9
pii: 10.1007/s00262-021-02912-9
pmc: PMC8505334
doi:
Substances chimiques
Antigens, Neoplasm
0
Retroviridae Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3183-3197Subventions
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 310030_182003/1
Organisme : H2020 European Research Council
ID : 670603
Informations de copyright
© 2021. The Author(s).
Références
Cancer Immunol Res. 2019 Apr;7(4):572-583
pubmed: 30782667
J Clin Oncol. 1989 Feb;7(2):250-61
pubmed: 2644399
N Engl J Med. 2016 Dec 8;375(23):2255-2262
pubmed: 27959684
Clin Cancer Res. 2011 Jul 1;17(13):4550-7
pubmed: 21498393
Ann Oncol. 2018 Nov 1;29(11):2183-2191
pubmed: 30239576
Clin Cancer Res. 2019 Jan 15;25(2):698-709
pubmed: 30327303
Science. 2015 Apr 3;348(6230):62-8
pubmed: 25838374
J Immunol. 2005 Oct 1;175(7):4797-805
pubmed: 16177129
J Immunol. 2014 Jun 15;192(12):5451-8
pubmed: 24907378
J Invest Dermatol. 2009 Dec;129(12):2835-42
pubmed: 19554023
Immunity. 2000 Aug;13(2):265-76
pubmed: 10981969
Int J Cancer. 2020 May 1;146(9):2518-2530
pubmed: 31374124
Science. 2002 Oct 25;298(5594):850-4
pubmed: 12242449
Mol Cancer. 2019 Aug 20;18(1):125
pubmed: 31429760
Clin Cancer Res. 2000 May;6(5):1997-2005
pubmed: 10815925
Nat Commun. 2017 May 22;8:15338
pubmed: 28530241
J Biol Chem. 2011 Dec 2;286(48):41723-41735
pubmed: 21990358
Eur J Immunol. 2020 Oct;50(10):1591-1597
pubmed: 32470143
J Immunother. 2012 Nov-Dec;35(9):651-60
pubmed: 23090074
Nat Med. 2017 Jan 6;23(1):18-27
pubmed: 28060797
Front Immunol. 2019 Dec 11;10:2857
pubmed: 31921127
Oncoimmunology. 2013 Nov 1;2(11):e26889
pubmed: 24482753
Nat Clin Pract Oncol. 2006 Dec;3(12):668-81
pubmed: 17139318
Int Immunol. 2003 Jul;15(7):797-805
pubmed: 12807818
Cancer Immunol Res. 2018 Feb;6(2):139-150
pubmed: 29180535
Nat Med. 2009 Jul;15(7):808-13
pubmed: 19525962
J Immunother Cancer. 2018 Oct 3;6(1):102
pubmed: 30285902
Nat Med. 2019 Jan;25(1):89-94
pubmed: 30510250
Immunol Rev. 2014 Jan;257(1):264-276
pubmed: 24329803
JCI Insight. 2019 May 16;4(10):
pubmed: 31092734
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73
pubmed: 12427970
Nat Med. 2006 Mar;12(3):335-41
pubmed: 16474399
Nat Med. 2018 Jun;24(6):724-730
pubmed: 29867227
JCI Insight. 2018 Sep 20;3(18):
pubmed: 30232291
Cancer Immunol Res. 2020 Apr;8(4):544-555
pubmed: 32047025
J Natl Cancer Inst. 1994 Aug 3;86(15):1159-66
pubmed: 8028037
Signal Transduct Target Ther. 2019 Sep 20;4:35
pubmed: 31637014
PLoS One. 2014 Oct 21;9(10):e109162
pubmed: 25334026
Clin Cancer Res. 2016 Jun 1;22(11):2734-43
pubmed: 26667491
Ann Oncol. 2019 Dec 1;30(12):1902-1913
pubmed: 31566658
Cancer Res. 2017 Jul 1;77(13):3644-3654
pubmed: 28484076
Cancer Cell. 2020 Jun 8;37(6):818-833.e9
pubmed: 32516591
Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9730-5
pubmed: 8790399
Sci Transl Med. 2018 Dec 5;10(470):
pubmed: 30518613
MAbs. 2021 Jan-Dec;13(1):1868066
pubmed: 33404287
Virchows Arch. 2019 Apr;474(4):449-461
pubmed: 30470934
J Clin Oncol. 2015 May 10;33(14):1543-50
pubmed: 25823737
Nat Rev Immunol. 2020 Oct;20(10):644
pubmed: 32873889
J Immunol. 2003 Feb 15;170(4):2161-9
pubmed: 12574389
Cancer Res. 2014 Dec 15;74(24):7168-74
pubmed: 25477332